Ann: Expanded Heart Protection Discovery for Zantrene, page-183

I am replying to myself as I don't know how to edit my previous post.

I have assumed that bisantrene will first be approved as a stand alone drug, but on reading your post again IndexInvestor, I am now thinking that the plan may be to take it straight into a new coformulation as it's only iteration. If that's the case, or the subject of the debate, then I do understand and all my comments are irrelevant to this option.
Of course under this premise if it were the SOC as the coformulation, and only available as such, then only giving part of it (drug x) would not be acceptable practice.